Takara Bio Inc
TSE:4974
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Takara Bio Inc
Long-Term Debt
Takara Bio Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Takara Bio Inc
TSE:4974
|
Long-Term Debt
¥10B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
51%
|
|
|
3
|
3-D Matrix Ltd
TSE:7777
|
Long-Term Debt
¥275.8m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Long-Term Debt
¥1.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
0%
|
|
|
GNI Group Ltd
TSE:2160
|
Long-Term Debt
¥3B
|
CAGR 3-Years
167%
|
CAGR 5-Years
68%
|
CAGR 10-Years
20%
|
|
|
PeptiDream Inc
TSE:4587
|
Long-Term Debt
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Long-Term Debt
¥76.4m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-13%
|
|
Takara Bio Inc
Glance View
Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,539 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
See Also
What is Takara Bio Inc's Long-Term Debt?
Long-Term Debt
10B
JPY
Based on the financial report for Dec 31, 2025, Takara Bio Inc's Long-Term Debt amounts to 10B JPY.
What is Takara Bio Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
51%